Fibrogen's Phase 3 Lelantos-1 Trial Of Pamrevlumab For Non-ambulatory Patients With Duchenne Muscular Dystrophy, Failed To Meet The Primary Endpoint Of Performance Of The Upper Limb 2.0 Score At Week 52 Compared To Baseline
Portfolio Pulse from Benzinga Newsdesk
Fibrogen's Phase 3 Lelantos-1 trial of Pamrevlumab for non-ambulatory patients with Duchenne Muscular Dystrophy failed to meet the primary endpoint of Performance of the Upper Limb 2.0 score at week 52 compared to baseline.
June 07, 2023 | 10:57 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fibrogen's Lelantos-1 trial failure may negatively impact the company's stock price in the short term.
The failure of Fibrogen's Phase 3 Lelantos-1 trial to meet its primary endpoint is a significant setback for the company. This negative news may lead to a decline in investor confidence and a short-term drop in the stock price of FGEN.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100